Volume | 2,266 |
|
|||||
News | - | ||||||
Day High | 2.02 | Low High |
|||||
Day Low | 1.95 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.95 | 1.95 | 2.02 | 1.955 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
27 | 2,266 | $ 2.00 | $ 4,531 | - | 1.3601 - 3.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:54:14 | 8 | $ 1.96 | USD |
Aeterna Zentaris Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.61M | 4.86M | - | 4.5M | -16.55M | -3.41 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aeterna Zentaris News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.95 | 2.02 | 1.95 | 1.95 | 13,017 | 0.03 | 1.54% |
1 Month | 1.98 | 2.26 | 1.95 | 2.05 | 15,058 | 0.00 | 0.00% |
3 Months | 1.89 | 2.39 | 1.68 | 1.99 | 16,659 | 0.09 | 4.76% |
6 Months | 1.56 | 2.51 | 1.3601 | 1.97 | 15,253 | 0.42 | 26.92% |
1 Year | 3.06 | 3.38 | 1.3601 | 2.28 | 12,719 | -1.08 | -35.29% |
3 Years | 0.93 | 5.90 | 0.1645 | 0.6949582 | 622,257 | 1.05 | 112.90% |
5 Years | 3.93 | 5.90 | 0.1645 | 1.14 | 1,849,216 | -1.95 | -49.62% |
Aeterna Zentaris Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |